Regeneron Pharmaceuticals (NASDAQ:REGN) Releases Earnings Results, Beats Expectations By $4.13 EPS

Regeneron Pharmaceuticals (NASDAQ:REGN) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported $14.29 EPS for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13, FiscalAI reports. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.Regeneron Pharmaceuticals’s revenue was up 16.7% on a year-over-year basis. During the same period last year, the business posted $12.81 earnings per share.

Here are the key takeaways from Regeneron Pharmaceuticals’ conference call:

• Strong second-quarter performance: Total revenue rose 17% year over year to $4.3 billion, while non-GAAP EPS increased 11% to $14.29. Dupixent, EYLEA HD, and Libtayo each reached record quarterly sales.
• Dupixent momentum remains robust, with global sales of $6 billion, up 38% at constant exchange rates, supported by growth across existing indications and newer launches. Growth is expected to remain strong, though it will moderate in the second half due to tougher comparisons.
• EYLEA HD is rapidly converting the U.S. franchise: sales increased 52% year over year to $596 million and exceeded legacy EYLEA sales for the first time. Regeneron is pursuing approval of a pre-filled syringe, which management believes could further improve adoption.
• Several pipeline catalysts are approaching, including potential FDA decisions for cemdisiran in generalized myasthenia gravis in November and garetosmab in FOP in August, along with data readouts for the PNH complement program and geographic atrophy program later this year.
• Legacy EYLEA remains under pressure: U.S. sales fell 45% year over year to $412 million as patients converted to EYLEA HD and competition increased. Management expects further low-to-mid-teens sequential demand declines in the second half, partly because of multiple aflibercept biosimilar launches.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded up $42.92 during trading on Thursday, reaching $738.34. 1,460,610 shares of the stock traded hands, compared to its average volume of 708,137. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.57 and a quick ratio of 2.96. The stock has a market capitalization of $78.06 billion, a P/E ratio of 17.99, a price-to-earnings-growth ratio of 27.78 and a beta of 0.24. Regeneron Pharmaceuticals has a 52-week low of $541.00 and a 52-week high of $821.11. The company has a 50-day moving average of $640.66 and a 200-day moving average of $711.35.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Stockholders of record on Tuesday, August 18th will be given a dividend of $0.94 per share. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.16%.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Results exceeded expectations: Regeneron reported second-quarter revenue of $4.29 billion, up 16.7% year over year and above the roughly $3.82 billion consensus estimate. Non-GAAP EPS was $14.29 versus expectations of approximately $10.16, helping drive renewed investor interest. Regeneron Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: Key growth products performed well: Dupixent sales, recorded by partner Sanofi, rose 38% to a record $6.0 billion, while U.S. EYLEA HD sales increased 52% to a record $596 million. Libtayo sales also grew 30% to $489 million, demonstrating strength beyond the company’s legacy EYLEA franchise. Regeneron beats quarterly estimates on eczema drug strength, shares rise
• Positive Sentiment: Pipeline and strategic expansion: Management highlighted its broader development pipeline, while a collaboration with Telix Pharmaceuticals could expand Regeneron’s oncology presence through next-generation radiopharmaceutical therapies. Why Regeneron is up after mixed Q2 results and Telix oncology deal
• Neutral Sentiment: Dividend declared: Regeneron announced a quarterly dividend of $0.94 per share, payable August 31 to shareholders of record August 18. The approximately 0.5% yield provides limited income support but is unlikely to be a major valuation driver.
• Neutral Sentiment: Broader sector weakness: Healthcare stocks declined late in the session, creating a headwind for the group even as Regeneron benefited from its earnings release.
• Negative Sentiment: Fianlimab-Libtayo trial litigation: Multiple law firms publicized a securities class action alleging that Regeneron misrepresented the risks and protocol changes surrounding the failed Phase 3 melanoma trial. The allegations relate to investors who purchased shares from August 1, 2025, through May 15, 2026; the lead-plaintiff deadline is September 14, 2026. The lawsuit follows an earlier, severe market reaction to the trial failure and could add legal costs and reputational risk, although the claims have not been proven. Hagens Berman Regeneron securities class action alert

Wall Street Analyst Weigh In

A number of brokerages have issued reports on REGN. Wells Fargo & Company reduced their price objective on Regeneron Pharmaceuticals from $800.00 to $700.00 and set an “equal weight” rating for the company in a research note on Monday, May 18th. BMO Capital Markets lowered their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. Guggenheim lifted their target price on Regeneron Pharmaceuticals from $995.00 to $1,000.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Truist Financial cut their price target on shares of Regeneron Pharmaceuticals from $778.00 to $769.00 and set a “buy” rating on the stock in a report on Tuesday, July 7th. Finally, Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a research report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $787.88.

Insiders Place Their Bets

In related news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the completion of the sale, the director owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Insigneo Advisory Services LLC raised its position in shares of Regeneron Pharmaceuticals by 3.0% in the fourth quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock valued at $343,000 after purchasing an additional 13 shares during the period. Guardian Wealth Advisors LLC NC boosted its holdings in Regeneron Pharmaceuticals by 3.3% in the 4th quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 14 shares during the period. Rexford Capital Inc. grew its stake in Regeneron Pharmaceuticals by 5.5% in the 4th quarter. Rexford Capital Inc. now owns 288 shares of the biopharmaceutical company’s stock valued at $222,000 after buying an additional 15 shares in the last quarter. Papamarkou Wellner Asset Management inc. grew its stake in Regeneron Pharmaceuticals by 4.7% in the 4th quarter. Papamarkou Wellner Asset Management inc. now owns 382 shares of the biopharmaceutical company’s stock valued at $295,000 after buying an additional 17 shares in the last quarter. Finally, Meeder Advisory Services Inc. raised its holdings in Regeneron Pharmaceuticals by 1.7% during the 4th quarter. Meeder Advisory Services Inc. now owns 1,250 shares of the biopharmaceutical company’s stock valued at $965,000 after acquiring an additional 21 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.